On September 30th, Pfizer entered an agreement with the Trump Administration to lower prices for its prescription drugs. In response to the four points covered in the President’s July 31st letter, Pfizer agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.  Specific terms of the agreement were not disclosed. Pfizer will also pa...